TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

• Status: Not yet recruiting
• Trial end date: 2025-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Patients with metastatic colorectal cancer (mCRC) who are scheduled to receive systemic cancer therapy have an increased risk for venous thromboembolic (VTE) events compared with the general population.

PROTINCOL is a randomized, open label, non placebo-controlled, low intervention, and phase III clinical trial that will recruit patients with mCRC. The study hypothesizes that prophylaxis with Tinzaparin could prevent the appearance of symptomatic and incidental VTE.

All patients will receive the first-line anticancer treatment deemed more appropriate according to the physician criteria. Enrolled patients are randomized in a 1:1 ratio (stratifying by BRAF/RAS, resection of primary tumor, and anti-angiogenic first-line treatment) to: control arm (no interventions related to VTE risk and no placebo) or experimental arm (prophylactic Tinzaparin at a fixed dose of 4500 IU/day in patients with up to 80kg, 6000 IU/day for those between 80-100 kg, or 8000 IU/day for those >100kg). Treatment is scheduled for a maximum period of 4 months. Treatment could be stopped earlier in case of unacceptable toxicity, patient consent withdrawal, physician criteria or end of study. Patients will undergo tumor and VTE assessments according to standard clinical practice.

The main objective of the study is to evaluate the efficacy of tinzaparin for the prevention of symptomatic or incidental VTE events. Secondary objectives include the associations between VTE events and tumor characteristics (i.e. laterality, RAS/BRAF mutations) or management (i.e. surgery or treatment with anti-angiogenic or anti-EGFR agents), cancer-specific survival outcomes, safety, the incidence of bleeding events, and patient-reported quality of life. The trial includes also a translational exploratory analysis to assess the predictive value of risk assessment models and genetic risk scores, their evolution through the study and microsatellite instability or other biomarkers.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Galician Research Group on Digestive Tumors
• Collaborator: LEO Pharma
• Treatments: Dalteparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

1. Male or female subjects with age ≥ 18 years.

2. Written informed consent.

3. Patients with a histologically confirmed diagnosis of stage IV colon or rectal adenocarcinoma (mCRC).

4. Locally assessed BRAF and RAS genomic alterations available during screening.

5. Beginning of the first line of treatment for metastatic disease with chemotherapy +/- targeted therapy (i.e. antiangiogenic, anti-EGFR, encorafenib-cetuximab doublet) or immunotherapy.

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

7. Life expectancy >6 months.

Exclusion Criteria:

1. Contraindication to tinzaparin, or other heparins:

1. Allergy (or hypersensitivity) to heparin, tinzaparin, other LMWHs, or pork products.

2. History or presence of heparin-induced (type II) thrombocytopenia.

3. Have or have had an epidural catheter or a traumatic spinal puncture within the previous 7 days.

2. Prothrombin time (PT) (International normalized ratio [INR] >1.5 for any reason) or aPTT >2 times control value.

3. Active major bleeding or conditions predisposing to major bleeding. a major bleeding is defined as one that meets one of the following three criteria:

1. occurring in a critical area or organ (for example, intracranial, intra-spinal, intraocular, retroperitoneal, intra-articular or pericardial, intrauterine or intramuscular with compartment syndrome),

2. causing a decrease in hemoglobin levels of 2 g/l (1.24 mmol/l) or more, or that requires a transfusion of two or more units of whole blood or packed red blood cells.

4. Lesions or conditions at increased risk of clinically significant bleeding, including:

1. Previously diagnosed/treated VTE ≤ 28 days prior to randomization.

2. Active ulcer disease.

3. Diagnosed cerebral metastases.

4. Stroke within the prior 6 months.

5. History of central nervous system (CNS) or intraocular bleeding.

5. Requirement of other anticoagulant therapy, dual antiplatelet therapy, daily non-steroidal anti-inflammatory drugs, or other medications known to increase the risk of bleeding.

Note: A daily dose of ≤100 mg of aspirin and single agent clopidogrel are permitted

6. Acute or chronic renal insufficiency with Creatinine clearance < 30 ml / min.

7. Platelet count < 80.000 /ml at the time of inclusion.

8. Severe liver insufficiency as defined by clinical manifestations of ascites, cirrhosis, encephalopathy and/or jaundice and/or biochemical abnormalities in liver function tests including:

1. elevated levels of total bilirubin (> 2 times the upper limit normal [ULN]),

2. elevated liver transaminases (> 2 times the ULN; > 5 in case of hepatic metastasis).

9. Participating in another study of an investigational agent at the time of enrollment. Note: Use of an experimental regimen of an approved product is not cause for exclusion.

10. Patients who weigh < 50 Kg.

11. Women of childbearing potential (WOCBP), must provide a negative serum or urine pregnancy test at screening. Women breastfeeding are not eligible.

Note: A pregnancy test is performed on WOCBP as per standard of care for patients undergoing anticancer treatments.

12. Any underlying medical or psychiatric disorder, which, in the opinion of the investigator, makes the administration of tinzaparin unsafe or interferes with the informed consent process or trial procedures.